Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026
Rhea-AI Summary
Treace Medical Concepts (NasdaqGS: TMCI) will release fourth-quarter and full-year 2025 financial results before market open on Friday, February 27, 2026.
Management will host a conference call at 8:00 am ET with live and archived webcast access via the company investor relations website. Investors must register to receive dial-in details and a unique PIN.
Positive
- None.
Negative
- None.
News Market Reaction – TMCI
In the Feb 13 session, TMCI declined 2.11%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2025-11-06 | Q3 2025 earnings | Negative | -0.3% | Reported Q3 2025 results with guidance cut and softer outlook. |
| 2025-08-07 | Q2 2025 earnings | Positive | +7.9% | Q2 2025 revenue growth, loss reduction, new products, guidance maintained. |
| 2025-05-08 | Q1 2025 earnings | Positive | -9.6% | Q1 2025 growth and margin strength with reaffirmed 2025 guidance. |
| 2025-02-27 | FY 2024 earnings | Positive | -2.1% | Q4 and 2024 revenue growth with improved profitability and 2025 guidance. |
| 2024-11-05 | Q3 2024 earnings | Positive | +35.1% | Q3 2024 revenue growth, margin strength, and guidance update. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases often drive sizable moves, with both strong rallies and notable selloffs, and several instances where positive fundamentals coincided with negative price reactions.
Over the past five earnings-related announcements from Nov 2024 through Nov 2025, Treace reported steady revenue growth and improving adjusted EBITDA, but also reduced revenue guidance in late 2025. Price reactions were mixed: strong gains followed some positive reports (e.g., Q3 2024, Q2 2025), while other upbeat releases, including Q1 2025 and FY 2024, saw declines. The current earnings-date update fits into this ongoing cadence of quarterly and annual financial disclosures.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the fourth quarter and full year of 2025 before the open of trading on Friday, February 27, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET.
Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.treace.com/.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for minimally invasive osteotomy procedures, namely the Nanoplasty® 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System, and the SpeedMTP® System. Treace continues to expand its footprint in the marketplace by extending its SpeedPlate® rapid compression implant platform to new applications, as well as providing surgeons with advanced digital solutions with its IntelliGuide® patient specific, pre-op planning and cut guide technology. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Philip Trip Taylor
IR@treace.net
